Developing countries face a fundamental healthcare challenge: diagnostic tests are too expensive. Western diagnostic kits cost $50 to $150 per test. Rural clinics in India, Africa, and Southeast Asia cannot afford these prices. Patients without money skip testing. Diseases spread undetected. HIV remains untreated. Malaria goes undiagnosed. Covid-19 infects communities unknowingly. The cost barrier prevents early detection, which is critical for saving lives. Oscar Bio addresses this problem by producing tests at 10 to 20 dollars per unit.
Oscar Medicare Pvt. Ltd. manufactures in New Delhi, India. Production costs are lower than in the US or Europe. Labor costs are 70% cheaper. Raw materials are sourced locally. This reduces the final price. A Covid-19 antigen test from Oscar Bio costs $3 instead of $30 from Western manufacturers. HIV tests cost $5 instead of $50. The price difference is tenfold. Rural clinics can now afford to test hundreds of patients instead of dozens. Outside the healthcare sector, affordability is also important on online gaming platforms, where users often compare features, promotions, and registration options before joining. Many players start by checking rocketplay sign up to create an account and explore the platform's available games and offers.
Production Scale Drives Cost Reduction
Oscar Bio produces 500,000 tests daily. During pandemic surges, production reached 1,000,000 tests per day. Mass production reduces per-unit costs through economies of scale. Manufacturing 1 million tests costs less per unit than manufacturing 10,000 tests. Fixed costs like machinery, facilities, and R&D are spread across more units. Variable costs like labor and materials decrease with bulk purchasing. This scaling effect is critical for affordability.
The company operates ISO 13485 certified facilities. Quality standards are maintained despite low costs. Poor quality would defeat the purpose. Tests must be accurate to be useful. Oscar Bio uses in-house clinical chemistry, serology, and lateral flow immunodiagnostics technologies. Complete in-house manufacturing eliminates outsourcing costs. Each component is produced internally, from antisera to molecular diagnostics reagents. This control reduces waste and increases efficiency.
30 Products Diagnosing 12 Critical Diseases
Oscar Bio offers 30 diagnostic products covering 12 diseases. The range includes rapid tests, ELISA kits, and serology kits. Diseases tested are Covid-19, HIV, HCV, HBsAg, Syphilis, Typhoid, Malaria, Dengue, Chikungunya, Troponin-I, Pregnancy, and Ovulation. Kala azar and H.pylori are also covered. This breadth means clinics can test for multiple conditions with one supplier. Bulk purchasing across products reduces overall costs further.
Each test serves a specific diagnostic need. Rapid tests provide results in 15 to 30 minutes. ELISA kits take 2 to 4 hours but offer higher sensitivity. Serology kits detect antibodies for past infections. The variety allows clinics to choose based on their resources. Rural clinics with limited equipment use rapid tests. Hospitals with labs use ELISA. This flexibility ensures affordability matches capability.
Here are the key affordable tests and their disease targets:
- Covid-19 Antigen Test: $3 per unit, detects active infection in 15 minutes
- HIV Rapid Test: $5 per unit, detects antibodies in 20 minutes
- Malaria Rapid Test: $4 per unit, identifies parasite in 15 minutes
- Troponin-I Test: $8 per unit, detects heart damage for early cardiac care
- Pregnancy Test: $1 per unit, confirms pregnancy in 5 minutes
Early Detection Prevents Costly Treatments
Affordable tests enable early detection. Early detection prevents disease progression. Untreated HIV becomes AIDS requiring $500 monthly medication. Detected HIV allows treatment at $50 monthly with antiretrovirals. The cost difference is 10-fold. Malaria untreated causes organ failure requiring hospitalization at $1000. Detected malaria is treated with $20 medication. Early testing saves money downstream.
Troponin-I tests detect heart damage before symptoms appear. Early cardiac care prevents major heart attacks requiring surgery at $50,000. Preventive care costs $100 annually. Pregnancy tests prevent unwanted complications through early planning. The economic benefit of early detection extends beyond test costs. It reduces hospitalization, surgery, and long-term medication expenses. Affordable tests are investments in preventing expensive emergencies.
Global Distribution Through 250 Partners
Oscar Bio sells through 250 qualified distribution partners across 30 countries. Direct distribution reduces intermediary costs. Western manufacturers use multiple distributors, each adding 15 to 20 percent markup. Oscar Bio's streamlined network keeps prices low. Partners include local pharmaceutical companies, medical supply distributors, and government health programs. This network ensures tests reach remote clinics.
The 30 countries include India, African nations, Southeast Asian countries, and Latin American nations. Each market has different healthcare infrastructure. Oscar Bio adapts distribution strategies accordingly. In India, tests sell through pharmacy chains. In Africa, they distribute through government health programs. In Southeast Asia, private clinics are primary customers. This flexibility ensures affordability matches local purchasing patterns.
First Self-Made Covid-19 Test in India
Oscar Bio developed India's first fully self-made Covid-19 antigen test. Previous tests used imported components from China or Europe. Import costs added 30 to 50 percent to prices. Self-manufacturing eliminated import dependency. All components are produced in India: antibodies, reagents, test strips, and packaging. This reduced the cost to $3 per test versus $30 for imported equivalents.
The self-made test was launched during pandemic surges when demand exceeded supply. Oscar Bio scaled production to 1 million tests daily. This volume ensured availability without price spikes. Other manufacturers raised prices during shortages. Oscar Bio maintained $3 pricing. The decision prioritized public health over profit. This approach built trust with government health programs and international buyers.
Challenges in Maintaining Quality at Low Cost
Achieving low costs while maintaining accuracy is difficult. Cheap tests sometimes produce false results. False negatives mean untreated infections spread. False positives cause unnecessary treatment and anxiety. Oscar Bio maintains ISO 13485 certification. Quality control involves testing every batch for accuracy. Sensitivity and specificity must exceed 95 percent. This standard is maintained despite low prices through efficient manufacturing.
In-house production allows quality control at each step. Raw materials are tested before use. Intermediate products are validated. Final products undergo accuracy testing. Rejected batches are destroyed. This prevents defective tests from reaching clinics. The cost of rejection is absorbed by scale. Manufacturing 500,000 tests means rejecting 5,000 is acceptable. The remaining 495,000 maintain low average costs.
Impact on Healthcare Access
Affordable tests increase healthcare access. Rural clinics test more patients. Mobile health teams carry tests to villages. Government programs distribute tests widely. Patients who previously skipped testing now get diagnosed. Disease prevalence data becomes accurate. Public health interventions target real problems. This improves overall healthcare outcomes. The economic benefit extends beyond individual patients to entire communities.
In India, Oscar Bio tests are used in government health camps. Thousands of villagers are tested for HIV, Malaria, and Typhoid in one day. Treatment begins immediately for positive cases. Disease transmission decreases. Similar programs occur in Africa and Southeast Asia. The tests enable mass screening campaigns that were previously financially impossible. Healthcare becomes proactive rather than reactive.
Future of Affordable Diagnostics
The trend toward affordable diagnostics is growing. More companies are developing low-cost tests. Technology improvements reduce production costs. Automation increases manufacturing efficiency. New materials like paper-based diagnostics are cheaper than plastic. Oscar Bio's success demonstrates the market exists. Demand for affordable tests is strong. Competition will drive prices lower while maintaining quality.
Future innovations include multiplex tests detecting multiple diseases simultaneously. One test for Covid-19, Malaria, and Dengue saves cost versus three separate tests. Molecular diagnostics become cheaper through simplified equipment. Portable devices enable testing without labs. These innovations will further reduce healthcare costs in developing countries. Affordable diagnostics will become standard rather than exceptional.
Conclusion: Affordability Enables Healthcare Access
Oscar Bio makes healthcare cheaper through affordable diagnostic tests. Production in India reduces costs by 70 percent versus Western manufacturers. Mass production of 500,000 tests daily drives per-unit costs down. The 30 products covering 12 diseases enable comprehensive testing. Early detection prevents costly treatments downstream. Global distribution through 250 partners ensures access. The first self-made Covid-19 test eliminated import dependency.
Affordable tests transform healthcare in developing countries. Rural clinics test more patients. Government programs conduct mass screening. Patients get diagnosed instead of skipping testing. Disease transmission decreases through early treatment. Healthcare becomes proactive rather than reactive. The economic benefit extends beyond test costs to prevent expensive emergencies. Oscar Bio's model proves affordability and quality coexist. Affordable diagnostics enable healthcare access for millions who previously lacked it.
